OBJECTIVE: To assess the use of complementary and alternative medicine (CAM) providers and the associated expenditures by specific treatment phases among patients with cancer. STUDY DESIGN: Cross-sectional analysis of medical services utilization and expenditures during the 3 therapeutic phases of initial, continuing, and end-of-life life treatment. METHODS: Analysis of an insurance claims database that had been matched to the Washington State Surveillance, Epidemiology, and End Results cancer registry. RESULTS: Of 2900 registry-matched patients, 63.2% were female, the median age was 54 years, and 92.7% were of white race/ethnicity. Breast cancer was the most frequent diagnosis (52.7%), followed by prostate cancer (24.7%), lung cancer (10.1%), colon cancer (7.0%), and hematologic malignancies (5.6%). Patients using CAM providers represented 26.5%. The proportion of patients using CAM was similar during each treatment phase. All patients used some conventional care. Age, female sex, breast cancer diagnosis, and white race/ethnicity were significant predictors of CAM use. Diagnosis of a musculoskeletal problem occurred at some time during the study for 72.1% of patients. CAM provider visits represented 7.2% of total outpatient medical visits, and 85.1% of CAM visits resulted in a musculoskeletal diagnosis. Expenditures for CAM providers were 0.3%, 1.0%, and 0.1% of all expenditures during the initial, continuing, and end-of-life phases, respectively. CONCLUSIONS: For patients with cancer, musculoskeletal issues were the most commonly listed diagnosis made by a CAM provider. Although expenditures associated with CAM are a small proportion of the total, additional studies are necessary to determine the importance that patients place on access to these services.
OBJECTIVE: To assess the use of complementary and alternative medicine (CAM) providers and the associated expenditures by specific treatment phases among patients with cancer. STUDY DESIGN: Cross-sectional analysis of medical services utilization and expenditures during the 3 therapeutic phases of initial, continuing, and end-of-life life treatment. METHODS: Analysis of an insurance claims database that had been matched to the Washington State Surveillance, Epidemiology, and End Results cancer registry. RESULTS: Of 2900 registry-matched patients, 63.2% were female, the median age was 54 years, and 92.7% were of white race/ethnicity. Breast cancer was the most frequent diagnosis (52.7%), followed by prostate cancer (24.7%), lung cancer (10.1%), colon cancer (7.0%), and hematologic malignancies (5.6%). Patients using CAM providers represented 26.5%. The proportion of patients using CAM was similar during each treatment phase. All patients used some conventional care. Age, female sex, breast cancer diagnosis, and white race/ethnicity were significant predictors of CAM use. Diagnosis of a musculoskeletal problem occurred at some time during the study for 72.1% of patients. CAM provider visits represented 7.2% of total outpatient medical visits, and 85.1% of CAM visits resulted in a musculoskeletal diagnosis. Expenditures for CAM providers were 0.3%, 1.0%, and 0.1% of all expenditures during the initial, continuing, and end-of-life phases, respectively. CONCLUSIONS: For patients with cancer, musculoskeletal issues were the most commonly listed diagnosis made by a CAM provider. Although expenditures associated with CAM are a small proportion of the total, additional studies are necessary to determine the importance that patients place on access to these services.
Authors: William E Lafferty; Lois Downey; Rachelle L McCarty; Leanna J Standish; Donald L Patrick Journal: Complement Ther Med Date: 2006-03-29 Impact factor: 2.446
Authors: J M Ezzo; M A Richardson; A Vickers; C Allen; S L Dibble; B F Issell; L Lao; M Pearl; G Ramirez; Ja Roscoe; J Shen; J C Shivnan; K Streitberger; I Treish; G Zhang Journal: Cochrane Database Syst Rev Date: 2006-04-19
Authors: K Robin Yabroff; William W Davis; Elizabeth B Lamont; Angela Fahey; Marie Topor; Martin L Brown; Joan L Warren Journal: J Natl Cancer Inst Date: 2007-01-03 Impact factor: 13.506
Authors: William E Lafferty; Patrick T Tyree; Allen S Bellas; Carolyn A Watts; Bonnie K Lind; Karen J Sherman; Daniel C Cherkin; David E Grembowski Journal: Am J Manag Care Date: 2006-07 Impact factor: 2.229
Authors: Michael Haake; Hans-Helge Müller; Carmen Schade-Brittinger; Heinz D Basler; Helmut Schäfer; Christoph Maier; Heinz G Endres; Hans J Trampisch; Albrecht Molsberger Journal: Arch Intern Med Date: 2007-09-24
Authors: Gabriella M John; Dawn L Hershman; Laura Falci; Zaixing Shi; Wei-Yann Tsai; Heather Greenlee Journal: J Cancer Surviv Date: 2016-02-26 Impact factor: 4.442
Authors: Sean M Devlin; Paula H Diehr; M Robyn Andersen; Barbara A Goff; Patrick T Tyree; William E Lafferty Journal: J Womens Health (Larchmt) Date: 2010-03 Impact factor: 2.681